Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621)
Verification report on the deposit and use of raised funds
Dahuhezi [2022] No. 001353
Dahua Certified Public Accountants (special general partnership)
DaHuaCertifiedPublicAccountants（SpecialGeneralPartnership）
Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621)
Verification report on the deposit and use of raised funds
(2021)
Table of contents page 1. Verification report on the deposit and use of raised funds 1-2 II. Special report on the deposit and actual use of raised funds from January to may in Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) 2021
Dahua Certified Public Accountants (special general partnership) 12 / F, building 7, yard 16, Middle West Fourth Ring Road, Haidian District, Beijing [100039] Tel: 86 (10) 58350011 Fax: 86 (10) 58350006 www.dahua-cpa. com. Verification report on the deposit and use of raised funds
Dahuhezi [2022] 001353 Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) all shareholders:
We have reviewed the attached Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) (hereinafter referred to as Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) ) special report on the deposit and actual use of raised funds in 2021 (hereinafter referred to as “special report on raised funds”).
1、 Responsibilities of the board of directors
Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) the responsibility of the board of directors is to comply with the regulatory guidelines for listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) of China Securities Regulatory Commission The guidelines for self-regulation of listed companies of Shanghai Stock Exchange No. 1 – standardized operation issued by Shanghai Stock Exchange and relevant format Guidelines shall prepare the special report on raised funds, and ensure that its content is true, accurate and complete without false records, misleading statements or major omissions.
2、 Responsibilities of Certified Public Accountants
Our responsibility is to give assurance opinions on the special report of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) raised funds based on the implementation of assurance work. We have carried out the assurance business in accordance with the provisions of other assurance business standards for Chinese certified public accountants No. 3101 – assurance business other than audit or review of historical financial information. Whether there is a major error in the assurance plan and the implementation of the assurance report.
Dahuhezi [2022] 001353 verification report on the deposit and use of raised funds
Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621)
Special report on the deposit and actual use of raised funds in 2021
1、 Basic information of raised funds
Approved by the reply on Approving the registration of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) initial public offering (zjxk [2021] No. 1629) of China Securities Regulatory Commission and approved by Shanghai Stock Exchange, the company issued 20 million ordinary shares (A shares) to the public by the lead underwriter Minsheng Securities Co., Ltd. on June 9, 2021, with a par value of 1 yuan per share, The issue price per share is RMB 26.89. As of June 16, 2021, the company has raised a total of 53780000000 yuan, deducting 7061850755 yuan of issuance expenses, and the net amount of raised funds is 46718149245 yuan.
As of June 16, 2021, all the funds raised by the above issuance of the company have been in place and have been verified and confirmed by Dahua Certified Public Accountants (special general partnership) with the capital verification report of “Dahua Yan Zi [2021] No. Zhang Jia Jie Tourism Group Co.Ltd(000430) “.
As of December 31, 2021, the company has invested 8694865337 yuan in the projects with raised funds, including 8694865337 yuan of raised funds used in this year. As of December 31, 2021, the balance of raised funds was RMB 23011621063.
2、 Management of raised funds
In order to regulate the management and use of raised funds and protect the rights and interests of investors, the company, in accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the stock listing rules of Shanghai Stock Exchange, the measures for the administration of raised funds of listed companies of Shanghai Stock Exchange and other laws and regulations, and in combination with the actual situation of the company, The management system of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) raised funds (hereinafter referred to as the “management system”) was formulated, which was deliberated and adopted by the third session of the first board of directors of the company on June 24, 2020 and voted by the third extraordinary general meeting of shareholders of the company on July 10, 2020.
According to the requirements of the management system, as required by the requirements of the management system, and in combination with the company’s operational needs, the company has opened a collection of solicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitsolicitations at the operating departments of the Bank Of Hangzhou Co.Ltd(600926) Bank Of Hangzhou Co.Ltd(600926) \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\specialfund account, In June 2021, it signed the tripartite supervision agreement on the storage of special account for raised funds with the deposit bank and the recommendation institution respectively, and implemented strict examination and approval procedures for the use of raised funds to ensure the special use of funds; The authorized recommendation representative may inquire the information of the special account for raised funds at the bank that has opened the special account for raised funds at any time, and require the recommendation representative to conduct on-site investigation on the management and use of raised funds at least once a quarter.
According to the tripartite supervision agreement on raised funds signed by the company with the deposit bank of raised funds and Minsheng Securities Co., Ltd
The company withdraws more than 50 million yuan from the deposit account of raised funds in a single time or within 12 months; and
The company shall notify the recommendation representative in writing if it has reached the raised capital and 20% of the net raised capital.
As of December 31, 2021, the storage of raised funds is listed as follows:
Monetary unit: RMB
Bank name account number initial deposit amount deadline balance storage method
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 110104016000013191191500000 China Union Holdings Ltd(000036) 96476086 current
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 1101040160000131910150000 Ping An Bank Co.Ltd(000001) 993872686 current account
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
China Merchants Bank Co.Ltd(600036) Co., Ltd. 110943202110302100000 China High-Speed Railway Technology Co.Ltd(000008) 797585952 current account
Si Beijing Dayun village sub branch
Industrial Bank Co.Ltd(601166) Co., Ltd. 3213 Liuzhou Iron&Steel Co.Ltd(601003) 40407100000 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 976998102 current account
Division Beijing Branch Changping sub branch
Bank Of Ningbo Co.Ltd(002142) Co., Ltd. 77170122 China Vanke Co.Ltd(000002) 1890398 Ping An Bank Co.Ltd(000001) 571506807 current account
Division Beijing Branch
Industrial Bank Co.Ltd(601166) Co., Ltd. 3213 Liuzhou Iron&Steel Co.Ltd(601003) 40516 — 197801516 current account
Beijing Changping sub branch Bank Of Ningbo Co.Ltd(002142) Co., Ltd
Current Beijing Changping sub branch business department 77170122 China Vanke Co.Ltd(000002) 671 — 9647843
Department
China Merchants Bank Co.Ltd(600036) Co., Ltd. 128908996810401 — 381657813 current account
Si Beijing Dayun village sub branch
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 11010401 Lucky Film Company Limited(600135) 5980 — 212.91 current account
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 1101040160000135956 — 1814908 current account
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 11010401 Lucky Film Company Limited(600135) 873 — 275671842 current account
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 11010401 Lucky Film Company Limited(600135) 8828 — 203110293 current account
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 11010401600001361343 — 718821904 current account
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 11010401600001361319 — 40460258 current account
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. 11010401600001368 — 146173762 current account
Division Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch
Total 490398 Shenzhen Universe (Group) Co.Ltd(000023) 011621063
3、 Use of raised funds in 2021
See the attached table “use of raised funds” for details.
4、 Change the use of funds for investment projects with raised funds
The company does not change the raised investment project or transfer or replace the raised investment project.
5、 Problems in the use and disclosure of raised funds
The information about the use of raised funds disclosed by the company is timely, true, accurate and complete, and the use of raised funds
There are no violations in and management.
6、 Concluding comments on the assurance report issued by the accounting firm on the deposit and use of the company’s annual raised funds Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) raised funds special report in all major aspects in accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (Revised in 2022) of the China Securities Regulatory Commission The measures for the administration of raised funds of listed companies of Shanghai Stock Exchange and the relevant format guidelines issued by Shanghai Stock Exchange fairly reflect the deposit and use of raised funds in Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) 2021 in all major aspects.
7、 Concluding comments on the special verification report issued by the sponsor on the deposit and use of the company’s annual raised funds
Verification opinions of Minsheng Securities Co., Ltd. on the deposit and use of raised funds in Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) 2021: Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) 2021 deposit and use of raised funds comply with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies In accordance with the provisions of relevant laws, regulations and system documents such as the guidelines for self-discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation and the Listing Rules of shares on the science and Innovation Board of Shanghai Stock Exchange, the raised funds have been stored and used in a special account, and the relevant information disclosure obligations have been fulfilled in a timely manner, The specific use of the raised funds is consistent with that disclosed by the company, and there is no disguised change in the purpose of the raised funds and damage to the interests of shareholders
